<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04500587</url>
  </required_header>
  <id_info>
    <org_study_id>ZN-d5-001</org_study_id>
    <nct_id>NCT04500587</nct_id>
  </id_info>
  <brief_title>Phase 1 First in Human Study of ZN-d5 as a Single Agent</brief_title>
  <official_title>Phase 1 First in Human Dose-Escalation Study of ZN-d5 as a Single Agent in Subjects With Non-Hodgkin Lymphoma or Acute Myeloid Leukemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>K-Group Alpha, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>K-Group Alpha, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase 1 dose escalation, open label, multicenter study, evaluating the safety,&#xD;
      tolerability, clinical activity, pharmacokinetics (PK) and pharmacodynamics (PD) of ZN-d5 in&#xD;
      subjects with Non-Hodgkin Lymphoma (NHL) and subjects with Acute Myeloid Leukemia (AML).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a Phase 1 dose escalation, open label, multicenter study, evaluating the safety,&#xD;
      tolerability, clinical activity, pharmacokinetics (PK) and pharmacodynamics (PD) of ZN-d5 in&#xD;
      subjects with Non-Hodgkin Lymphoma (NHL) and subjects with Acute Myeloid Leukemia (AML). NHL&#xD;
      subjects will continue to dose escalate until either the MTD or the RP2D is identified.&#xD;
&#xD;
      Subjects with AML will start enrolling into the trial once a safe dose is identified in&#xD;
      subjects with NHL.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 13, 2020</start_date>
  <completion_date type="Anticipated">May 2023</completion_date>
  <primary_completion_date type="Anticipated">October 2022</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To investigate the incidence of treatment-emergent Adverse Events f ZN-d5 in subjects with NHL and AML</measure>
    <time_frame>AEs through Phase 1 completion, an average of 1 year and DLTs through Cycle 1 (each cycle is 21 days) In Phase 1, an average of 1 year</time_frame>
    <description>Observed Dose Limiting Toxicities (DLTs) in DLT evaluable subjects in order to evaluate safety and tolerability.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>To determine the maximum tolerated dose (MTD) in NHL and AML</measure>
    <time_frame>Through study completion, an average of 2 years</time_frame>
    <description>Incidence and severity of AEs, graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE), v 5.0</description>
  </primary_outcome>
  <primary_outcome>
    <measure>To determine the recommended Phase 2 dose (RP2D) in NHL and AML</measure>
    <time_frame>Through study completion, an average of 2 years</time_frame>
    <description>Incidence and severity of AEs, graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE), v 5.0</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>To investigate the clinical activity of ZN-d5 in subjects with NHL and AM</measure>
    <time_frame>Through study completion, an average of 2 years</time_frame>
    <description>For NHL, as defined by the Lugano response criteria for NHL;For AML - clinical activity will be assessed based on ELN Response Criteria</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">85</enrollment>
  <condition>Acute Myeloid Leukemia</condition>
  <condition>Non Hodgkin Lymphoma</condition>
  <arm_group>
    <arm_group_label>Znd5 Single Agent Dose Escalation - NHL</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL), marginal zone lymphoma (MZL), Mantle Cell Lymphoma (MCL), large cell lymphoma (LCL), and peripheral T-cell lymphoma (PTCL). Subjects must have relapsed or be refractory to at least 2 prior lines of therapy and have either failed or were not eligible for any available therapies expected to provide clinical benefit.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Znd5 Single Agent Dose Escalation - AML</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects with relapsed and/or primary refractory AML as defined by WHO 2016 revised criteria, who have either relapsed or are refractory to previously available therapy.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ZN-d5</intervention_name>
    <description>Oral agent; 25 mg or 100 mg formulation</description>
    <arm_group_label>Znd5 Single Agent Dose Escalation - AML</arm_group_label>
    <arm_group_label>Znd5 Single Agent Dose Escalation - NHL</arm_group_label>
    <other_name>Study Drug</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        • Inclusion Criteria Applicable for all Indications&#xD;
&#xD;
        White blood cell (WBC) count &lt; 25 × 109/L. Cytoreduction prior to treatment is acceptable.&#xD;
&#xD;
        Female subjects of childbearing potential must have a negative serum beta human chorionic&#xD;
        gonadotropin (βHCG) test.&#xD;
&#xD;
        Male subjects and female subjects of childbearing potential must agree to use an effective&#xD;
        method of contraception per institutional standard prior to the first dose and for 90 days&#xD;
        after the last dose of ZN-d5.&#xD;
&#xD;
        Eastern Cooperative Oncology Group (ECOG) performance status ≤ 1&#xD;
&#xD;
        Use of antifungal agents such as fluconazole is permitted except posaconazole and&#xD;
        voriconazole, which are not permitted.&#xD;
&#xD;
        - Inclusion Criteria for NHL&#xD;
&#xD;
        Histologically or cytologically confirmed relapsed (recurrent after previous therapy) or&#xD;
        refractory (no response to previous therapy) NHL based on the World Health Organization&#xD;
        (WHO) criteria as determined by pathology review at the study site.&#xD;
&#xD;
        Subject must have received at least 2 prior lines of therapy and have either failed or were&#xD;
        not eligible for any available therapies expected to provide clinical benefit.&#xD;
&#xD;
        For DLBCL, subjects should have failed CHOP or R-CHOP therapy and have failed salvage&#xD;
        therapy including stem cell transplant, or not be candidates for these therapies.&#xD;
&#xD;
        Subjects with B-cell NHL should have failed anti-CD20 therapy and anthracycline-based&#xD;
        therapy, or not be candidates for these therapies.&#xD;
&#xD;
        Subjects with indolent lymphomas should meet clinical criteria for treatment. . Adequate&#xD;
        hematologic and organ function as defined by the following criteria: ANC ≥ 1.0 × 109/L&#xD;
        after at least 7 days post the last dose of a growth factor&#xD;
&#xD;
        Platelet count ≥ 75 × 109/L; excluding measurements obtained within 3 days after&#xD;
        transfusion of platelets. A platelet count of ≥ 50 × 109/L is allowed if the percentage of&#xD;
        lymphoma cells in the bone marrow is &gt; 50%.&#xD;
&#xD;
        Hemoglobin ≥ 8.0 g/dL after at least 7 days post the last transfusion or growth factor&#xD;
        Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤ 3 × upper limit of&#xD;
        normal (ULN). If liver function abnormalities are due to underlying liver involvement, AST&#xD;
        and ALT ≤ 5 × ULN.&#xD;
&#xD;
        Total serum bilirubin ≤ 1.5 × ULN or no limit in the case of Gilbert's disease Serum&#xD;
        creatinine ≤ 1.5 × ULN or creatinine clearance (CrCl) ≥ 60 mL/min;&#xD;
&#xD;
        - Inclusion Criteria for AML&#xD;
&#xD;
        Relapsed and/or primary refractory AML as defined by WHO 2016 revised criteria&#xD;
&#xD;
        Subjects must have AML, relapsed or refractory to previously available therapy.&#xD;
&#xD;
        Adequate organ function as defined by the following criteria:&#xD;
&#xD;
        Total serum bilirubin &lt; 1.5 × ULN or no limit in the case of Gilbert's disease&#xD;
&#xD;
        AST/ALT ≤ 3 × ULN. Levels of AST and/or ALT ≤ 5 × the ULN may be acceptable for subjects&#xD;
        with known leukemic involvement of the liver after discussion with the study Medical&#xD;
        Monitor.&#xD;
&#xD;
        Serum creatinine &lt; 1.5 × ULN or CrCL ≥ 60 mL/min;&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        • Exclusion Criteria Applicable to the Study and Indications&#xD;
&#xD;
        Any of the following treatment interventions within the specified time frame prior to Cycle&#xD;
        1 Day 1/Ramp-up Cycle Day 1:&#xD;
&#xD;
        Major surgery (the surgical incision should be fully healed prior to study drug&#xD;
        administration).&#xD;
&#xD;
        Radiation therapy&#xD;
&#xD;
        Presence of a clinically significant nonhematologic toxicity of prior chemotherapy that has&#xD;
        not resolved to ≤ Grade 1 or Baseline, whichever is greater, as determined by CTCAE v 5.0&#xD;
        (Section 14.2), with the exception of alopecia, neuropathy or skin pigmentation.&#xD;
&#xD;
        Autologous or allogeneic stem cell transplant&#xD;
&#xD;
        Receiving immunosuppression or having active fungal disease or active graft- versus-host&#xD;
        disease after allogeneic stem cell transplantation on Cycle 1 Day 1/ Ramp-up Cycle Day 1.&#xD;
&#xD;
        Current use of an investigational agent that is not expected to be cleared by the first&#xD;
        dosing of study drug or that has demonstrated to have prolonged side effects.&#xD;
&#xD;
        A serious illness or medical condition(s) including, but not limited to, the following:&#xD;
&#xD;
        Unstable brain lymphoma with clinical symptoms.&#xD;
&#xD;
        Known active Central Nervous System (CNS) leukemia. Controlled CNS leukemia is defined by&#xD;
        the absence of active clinical signs of CNS disease and no evidence of CNS leukemia on the&#xD;
        most recent 2 simultaneous cerebral spinal fluid (CSF) evaluations.&#xD;
&#xD;
        Subjects with myocardial impairment of any cause (e.g., cardiomyopathy, ischemic heart&#xD;
        disease, significant valvular dysfunction, hypertensive heart disease, and congestive heart&#xD;
        failure) resulting in heart failure by New York Heart Association (NYHA) Classification&#xD;
        (Class III or IV).&#xD;
&#xD;
        Acquired immunodeficiency syndrome (AIDS) related illness or hepatitis B or C with&#xD;
        cirrhosis of the liver.&#xD;
&#xD;
        Other severe acute or chronic medical or psychiatric condition or laboratory abnormality&#xD;
        that may increase the risk associated with study participation or study drug&#xD;
        administration, or may interfere with the interpretation of study results, and in the&#xD;
        judgment of the&#xD;
&#xD;
        Significant gastrointestinal abnormalities, including an inability to take oral medication,&#xD;
        requirement for IV alimentation, active peptic ulcer, chronic diarrhea or vomiting&#xD;
        considered to be clinically significant in the judgment of the Investigator, or prior&#xD;
        surgical procedures affecting absorption.&#xD;
&#xD;
        Active or uncontrolled infection. Subjects with an infection receiving treatment&#xD;
        (antibiotic, antifungal or antiviral treatment) may be entered into the study but must be&#xD;
        afebrile and hemodynamically stable for ≥ 72 hours.&#xD;
&#xD;
        Current evidence of invasive fungal infection (blood or tissue culture); subjects with&#xD;
        recent fungal infection must have a subsequent negative culture to be eligible.&#xD;
&#xD;
        Prior therapy with venetoclax.&#xD;
&#xD;
        Pregnant or lactating females (including the cessation of lactation) or females of&#xD;
        childbearing potential who have a positive pregnancy test (urine or serum)&#xD;
&#xD;
        Subjects with active (uncontrolled, metastatic) second malignancies.&#xD;
&#xD;
        Subjects who are judged by the Investigator to be unsuitable as study subjects. 12 lead&#xD;
        electrocardiogram (ECG) demonstrating a QTcF of &gt; 480 msec, except for subjects with&#xD;
        atrioventricular pacemakers or other conditions (e.g., right bundle branch block) that&#xD;
        render the QT measurement invalid.&#xD;
&#xD;
        History or current evidence of congenital long QT syndrome. Taking medications that lead to&#xD;
        significant QT prolongation.&#xD;
&#xD;
        Administration of strong CYP3A4 inhibitors or strong or moderate CYP3A4 inducers&#xD;
&#xD;
        - Exclusion Criteria for AML&#xD;
&#xD;
        Any prior systemic neoplastic agents within 14 days or at least 5 half-lives (whichever is&#xD;
        shorter) for cytotoxic/noncytotoxic agents.&#xD;
&#xD;
        Hydroxyurea, hematopoietic growth factors, or tretinoin (all trans-retinoic acid) are&#xD;
        allowed for subjects with rapidly proliferative disease, up to 24 hours before Ramp-up&#xD;
        Cycle Day 1 and for the first 7 days of Cycle 1 for peripheral blast control. One dose of&#xD;
        cytarabine (up to 2 g/m2) is allowed for subjects with rapidly proliferative disease, up to&#xD;
        48 hours before Ramp-up Cycle Day#1.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Anthony Fiorino, MD</last_name>
    <role>Study Director</role>
    <affiliation>K-Group Alpha</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Anthony Fiorino, MD</last_name>
    <phone>8582634333</phone>
    <email>info@zenopharma.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Site 2708</name>
      <address>
        <city>Darlinghurst</city>
        <state>New South Wales</state>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Site 2704</name>
      <address>
        <city>Liverpool</city>
        <state>New South Wales</state>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Site 2709</name>
      <address>
        <city>Hobart</city>
        <state>Tasmania</state>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Site 1202</name>
      <address>
        <city>Sofia</city>
        <country>Bulgaria</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Site 1203</name>
      <address>
        <city>Varna</city>
        <country>Bulgaria</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Site 3201</name>
      <address>
        <city>Zagreb</city>
        <country>Croatia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Site 2901</name>
      <address>
        <city>Pusan</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Site 2903</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Site 2403</name>
      <address>
        <city>Gdansk</city>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Site 3001</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Site 3001</name>
      <address>
        <city>Valencia</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Site 2001</name>
      <address>
        <city>Kiev</city>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Bulgaria</country>
    <country>Croatia</country>
    <country>Korea, Republic of</country>
    <country>Poland</country>
    <country>Spain</country>
    <country>Ukraine</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>July 30, 2020</study_first_submitted>
  <study_first_submitted_qc>August 3, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">August 5, 2020</study_first_posted>
  <last_update_submitted>July 22, 2021</last_update_submitted>
  <last_update_submitted_qc>July 22, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 29, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Blood Cancers</keyword>
  <keyword>Liquid Tumors</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Leukemia, Myeloid, Acute</mesh_term>
    <mesh_term>Lymphoma, Non-Hodgkin</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

